Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $5.2600 (-5.14%) ($5.2600 - $5.2600) on Fri. Apr. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.08% (three month average) | RSI | 36 | Latest Price | $5.2600(-5.14%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.3% a day on average for past five trading days. | Weekly Trend | AUTL declines -2.6% a week on average for past two weeks. | Market Behavior | Value stock rally for large cap. Normal for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) BNDX(12%) TLT(11%) BND(9%) XLRE(9%) LQD(7%) | Factors Impacting AUTL price | AUTL will decline at least -2.04% in a week (0% probabilities). TBT(-11%) UNG(-8%) USO(-6%) XLF(-5%) EDOC(-5%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.04% (StdDev 4.08%) | Hourly BBV | -1.3 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-8.09(-253.8%) | Resistance Level | $5.82 | 5 Day Moving Average | $5.47(-3.84%) | 10 Day Moving Average | $5.6(-6.07%) | 20 Day Moving Average | $5.82(-9.62%) | To recent high | -41.9% | To recent low | 0% | Market Cap | $275m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |